Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + eribulin
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin (Adriamycin), and eribulin mesylate. Cyclophosphamide is an alkylating agent that stops cancer cells from reproducing by damaging their DNA. Doxorubicin is an anthracycline that stops cancer cells from making DNA and interferes with the enzymes that repair DNA in cells. Eribulin is a microtubule inhibitor that belongs to the halichondrin class of antineoplastic drugs. This combination has been studied in clinical trials for the treatment of breast cancer, particularly HER2-negative breast cancer.
- Other names
- AC followed by eribulinNeoadjuvant AC-Eribulin
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + eribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + eribulin.